Long-term data with evinacumab in homozygous familial hypercholesterolaemia (FH) This novel ANGPTL3-directed therapy was effective and well tolerated in the longer-term in adults and adolescents with homozygous FH on aggressive lipid lowering therapy.
Will evinacumab eliminate the need for LDL-apheresis in patients with homozygous FH? Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) gives his view.
